PremiumRatingsStrategic Resilience and Growth Potential: A Buy Rating for PTC Therapeutics Amid Regulatory Challenges PTC Therapeutics: Strategic Growth and Market Expansion Justify Buy Rating Amid Regulatory Challenges PTC Therapeutics Faces EU Setback on Translarna PremiumThe FlyPTC Therapeutics price target raised to $50 from $46 at Citi PTC Therapeutics upgraded to Neutral from Underperform at BofA Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls PremiumRatingsPTC Therapeutics Faces Regulatory and Revenue Challenges: Analyst Maintains Sell Rating PTC Therapeutics: Buy Rating Backed by Promising Clinical Catalysts and Solid Commercial Foundation PTC Therapeutics price target lowered to $72 from $74 at JPMorgan 
